<DOC>
	<DOCNO>NCT00347126</DOCNO>
	<brief_summary>Prostaglandin analog lead class glaucoma drug proven safety efficacy control IOP . They include latanoprost , bimatoprost , travoprost unoprostone . Recently , Singapore National Eye Center ( SNEC ) award tender prostaglandin analogue Alcon , manufacturer travoprost . Since , subsidized patient previously treat latanoprost systematically switch travoprost process continue rest year . In study , propose prospectively study efficacy safety switch latanoprost travoprost large series glaucoma patient SNEC . A total 372 consecutive patient switch latanoprost travoprost follow 12 week follow switch . In addition intraocular pressure , safety tolerability ( particular emphasis hyperemia ) travoprost examine .</brief_summary>
	<brief_title>Results Mass Switch From Latanoprost Travoprost</brief_title>
	<detailed_description>Aims : 1 . To assess feasibility switch large group patient treatment latanoprost travoprost . 2 . To assess efficacy safety travoprost compare latanoprost switch . Intraocular pressure ( IOP ) currently prove modifiable risk factor management glaucoma.1 Either medical surgical management achieve control IOP . Prostaglandin analog new class drug among various topical ocular hypotensive medication , proven safety efficacy control IOP.2 Their potency day dose low incidence systemic side effect make popular use monotherapeutic first-line agent . They include latanoprost , bimatoprost , travoprost unoprostone . All similar molecular structure work increase aqueous drainage via trabecular meshwork uveoscleral pathway.3 It show efficacy latanoprost , bimatoprost travoprost reduce IOP ocular hypertension primary open angle glaucoma comparable.4 Conjunctival hyperemia one common ocular side effect . There report high incidence hyperemia bimatoprost travoprost compare latanoprost.4 However , hyperemia usually benign usually abate drug use long term . The incidence discontinuation therapy due hyperemia low different among various prostaglandins.5 Among prostaglandin analogue , latanoprost market leader Singapore past year . However , Singapore National Eye Center ( SNEC ) pharmacy recently accept tender various drug company prostaglandin analog . Alcon , manufacturer travoprost award tender . Since , subsidized patient previously treat latanoprost systematically switch travoprost process continue rest year . The switch systematic switch base intolerance poor response latanoprost . To date , single report regard feasibility efficacy mass switch latanoprost bimatoprost.5 The study report high switch rate good IOP control minimal switch back . However , similar data switch latanoprost travoprost lacking . In study , propose prospectively study efficacy safety switch latanoprost travoprost large series glaucoma patient SNEC . A total 372 consecutive patient switch latanoprost travoprost follow 12 week follow switch . In addition IOP , safety tolerability ( particular emphasis hyperemia ) travoprost examine . References : 1 . Leske MC , Heijl A , Hussein M et al . Factors glaucoma progression effect treatment : early manifest glaucoma trial . Arch Ophthalmol . 2003 Jan ; 121 ( 1 ) :48-56 . 2 . Alexander CL , Miller SJ , Abel SR. Prostaglandin analog treatment glaucoma ocular hypertension . Ann Pharmacother . 2002 Mar ; 36 ( 3 ) :504-11.3 . 3 . Eisenberg DL , Toris CB , Camras CB . Bimatoprost travoprost : review recent study two new glaucoma drug . Surv Ophthalmol . 2002 Aug ; 47 Suppl 1 : S105-15 . 4 . Parrish RK , Palmberg P , Sheu WP ; XLT Study Group . A comparison latanoprost , bimatoprost , travoprost patient elevate intraocular pressure : 12-week , randomize , masked-evaluator multicenter study . Am J Ophthalmol . 2003 May ; 135 ( 5 ) :688-703 . 5 . Law SK , Song BJ , Fang E , Caprioli J. Feasibility efficacy mass switch latanoprost bimatoprost glaucoma patient prepay Health Maintenance Organization . Ophthalmology . 2005 Dec ; 112 ( 12 ) :2123-30 .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>1 . Patients treatment latanoprost least 12 week ; patient additional betablockers topically also eligible . 2 . Written informed consent . 1 . Patients 3 topical medication . 2 . Recorded history intolerance travoprost . 3 . Recorded history inefficacy travoprost control IOP . 4 . Patients additional topical medication betablockers . 5 . History noncompliance . 6 . Involvement concomitant study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Latanoprost</keyword>
	<keyword>Travoprost</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>Hyperemia</keyword>
</DOC>